CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients

Hyperinflammation distinguishes COVID-19 patients who develop a slight disease or none, from those progressing to severe and critical conditions. CIGB-258 is a therapeutic option for the latter group of patients. This drug is an altered peptide ligand (APL) derived from the cellular stress protein 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez-Cedeño, M., Venegas-Rodriguez, R., Peña-Ruiz, R., Bequet-Romero, M., Santana-Sanchez, R., Penton-Arias, E., Martinez-Donato, G., Guillén-Nieto, G., Dominguez-Horta, María del Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904296/
https://www.ncbi.nlm.nih.gov/pubmed/33629254
http://dx.doi.org/10.1007/s12192-021-01197-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904296/
https://www.ncbi.nlm.nih.gov/pubmed/33629254
http://dx.doi.org/10.1007/s12192-021-01197-2

Ejemplares similares